Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 546-554 , November 2005

Preventing radiation induced xerostomia

  • Michael I. Koukourakis

      Affiliations

    • Department of Radiotherapy – Oncology, Medical School, Democritus University of Thrace, Tumour & Angiogenesis Research Group, P.O. Box 12, Alexandroupolis 68100, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30 69324 80808; fax: +30 25510 30349.
    • ,
  • Vassilios Danielidis

      Affiliations

    • Department of Radiotherapy – Otorhinolaryngology Clinic, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

References 

  1. Moller T. Head and neck cancer. Acta Oncol. 1996;35(Suppl 7):22–45
  2. Trotti A, Garden A, Warde P, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004;58:674–681
  3. Dahiya MC, Redding SW, Dahiya RS, et al. Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external beam radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003;57:79–83
  4. Valdez IH, Atkinson JC, Ship JA, Fox PC. Major salivary gland function in patients with radiation-induced xerostomia: flow rates and sialochemistry. Int J Radiat Oncol Biol Phys. 1993;25:41–47
  5. Hendry JH. Treatment acceleration in radiotherapy: the relative time factors and dose–response slopes for tumors and normal tissues. Radiother Oncol. 1992;25:308–312
  6. Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose fractionation and regeneration of the oral cavity and oropharynx: tumor dose–response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831–843
  7. Chen Y, Okunieff P. Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am. 2004;18:55–80
  8. Curran WJ. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology. 2002;63(Suppl. 2):29–38
  9. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G, et al. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer. 2002;87:385–392
  10. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004;58:1369–1377
  11. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  12. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997;44:111–121
  13. Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:1105–1108
  14. Koukourakis MI. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol. 2002;29(6 Suppl 19):42–46
  15. Purdy JA. 3D treatment planning and intensity-modulated radiation therapy. Oncology (Huntingt). 1999;13(10 Suppl 5):155–168
  16. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51:880-914.
  17. Goffman TE, Glatstein E. Intensity-modulated radiation therapy. Radiat Res. 2002;158:115–117
  18. Grdina DJ, Sigdestad CP. Radiation protectors: the unexpected benefits. Drug Metab Rev. 1989;20:13–42
  19. Nakamura J, Shaw LM, Brown DQ. Hydrolysis of WR-2721 by mouse liver cell fractions. Radiat Res. 1987;109:143–152
  20. Mori T, Nikaido O, Sughara T. Dephosphorylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys. 1984;10:1529–1531
  21. Giatromanolaki A, Sivridis E, Maltezos E, Koukourakis MI. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol. 2002;29(Suppl 19):14–21
  22. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6(1):15–19
  23. Koukourakis MI. Amifostine: is there evidence of tumor protection?. Semin Oncol. 2003;30(Suppl 18):18–30
  24. Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs. 2002;13:181–209
  25. Koukourakis MI. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol. 2002;29(Suppl 19):42–46
  26. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18:2226–2233
  27. Jensen AB, Hansen O, Jorgensen K, Bastholt L. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer. Acta Oncol. 1994;33:487–491
  28. Huguenin PU, Taussky D, Moe K, et al. Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: the importance of the target volume. Int J Radiat Oncol Biol Phys. 1999;45:47–52
  29. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345
  30. Price RE, Ang KK, Stephens LC, Peters LJ. Effects of continuous hyperfractionated accelerated and conventionally fractionated radiotherapy on the parotid and submandibular salivary glands of rhesus monkeys. Radiother Oncol. 1995;34:39–46
  31. Wynn RL. Oral pilocarpine (Salagen) – a recently approved salivary stimulant. Gen Dent. 1996;44:29–30
  32. Valdez IH, Wolff A, Atkinson JC, et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer. 1993;71:1848–1851
  33. Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck. 1997;19:169–175
  34. Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer – RTOG 97-09. Int J Radiat Oncol Biol Phys. 2003;56:832–836
  35. Senahayake F, Piggott K, Hamilton-Miller JM. A pilot study of Salix SST (saliva-stimulating lozenges) in post-irradiation xerostomia. Curr Med Res Opin. 1998;14:155–159
  36. Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer. 1987;59:1123–1125
  37. Schuller DE, Stevens P, Clausen KP, et al. Treatment of radiation side effects with oral pilocarpine. J Surg Oncol. 1989;42:272–276
  38. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol. 1993;11:1124–1131
  39. Warde P, O’Sullivan B, Aslanidis J, et al. A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;54:9–13
  40. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49:907–916
  41. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12–22
  42. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma. Cancer. 2004;10:1584
  43. Munter MW, Karger CP, Hoffner SG, et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys. 2004;58:175–184
  44. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;58:663–673
  45. Pacholke HD, Amdur RJ, Morris CG, et al. Xerostomia quality of life in HNC patients who are beyond the acute recovery pahse following radiotherapy: IMRT versus Conventional Radiotherapy. ASTRO 2004 (Abstr. 2256), Atlanta, USA.
  46. Lauve A, Moris M, Schmidt-Ullrich R, et al. Simultaneous integrated boost IMRT for locally advanced HNC: II – clinical results. Int J Radiat Oncol Biol Phys. 2004;60:374–387
  47. Bohuslavizki KH, Klutmann S, Brenner W, et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol. 1998;16:3542–3549
  48. Buntzel J, Kuttner K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998;9:505–509
  49. Mackowiak JI, Scott-Lennox J, Lennox R, et al. Patient benefit questionnaire (PBQ) for xerostomia: development and validation report. Value Health. 1999;2:197;(abstr)
  50. Wasserman T, Mackowiak JI, Brizel DM, et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys. 2000;48:1035–1039
  51. Ringash J, Warde P, Lockwood G, O’Sullivan B, Waldron J, Cummings B. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys. 2005;61:1403–1407
  52. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy +/− amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlenther Onkol. 2003;179:385–389
  53. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–747
  54. Rudat V, Meyer J, Momm F, et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys. 2000;48:1339–1343
  55. Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, et al. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncol. 2003;39:397–401
  56. Koukourakis MI, Bizakis JG, Skoulakis CE, et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res. 1999;19:2305–2309
  57. Chougule PB, Akhtar MS, Akerley W, et al. Chemoradiotherapy for advanced inoperable head and neck cancer: a phase II study. Semin Radiat Oncol. 1999;9(2 Suppl 1):58–63
  58. Abitbol A, Lewin A, Rodrigues MA, et al. Sequential trial of concurrent hyperfractionated radiation therapy and 5-fluorouracil, cisplatin and paclitaxel with and without amifostine in patients with locally advanced head and neck squamous cell carcinoma. Proc Am Soc Clin Oncol. 2001;20:228a
  59. Jha N, Seikaly H, McGaw T, Coulter L. Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys. 2000;46:7–11
  60. Seikaly H, Jha N, McGaw T, et al. Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope. 2001;111:347–352
  61. Seikaly H, Jha N, Harris JR, et al. Long-term outcomes of submandibular gland transfer for prevention of postradiation xerostomia. Arch Otolaryngol Head Neck Surg. 2004;130:956–961
  62. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895–2903
  63. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Semin Oncol. 2002;29(Suppl 19):2–8

PII: S0305-7372(05)00128-3

doi: 10.1016/j.ctrv.2005.07.006

Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 546-554 , November 2005

Article Tools

* Image Usage & Resolution